Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare Biotechnology

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

Bullboard Posts

Post by MasterAlgaeon Nov 19, 2020 9:45am

1053 Views

Post# 31929934

NASDAQ is a certainty

Antibe qualifies to list on NASDAQ under the NASDAQ Capital Market Criteria - the least stringent of the three grades of NASDAQ listing.

The reuqirements would allow for a listing under the closing price alternative of $3USD per share, Antibe just squeeks through by having annual revenues of 6 million USD, (they have 6.4 million at today's exchange rate).

A reverse at .40 cents would be $3.10 USD - crossing the threshold by a dime.

The premier listing would be NASDAQ Global Select Market. Antibe could also qualify under this criteria as well. The minimum bid for that requirement is $4 or $5.25CAD post reverse or .525 pre-reverse.

So, I think we have a fairly clear minimum range in front of us.

Bullboard Posts

Quantum eMotion leaps by 20 per cent after Becton Dickinson deal